SC 13G/A | 2016-06-06 | Boxer Capital, LLC | Eleven Biotherapeutics, Inc. | 2,255,572 | 11.3% | EDGAR |
SC 13G | 2016-05-25 | Boxer Capital, LLC | Eleven Biotherapeutics, Inc. | 1,505,572 | 7.5% | EDGAR |
SC 13G/A | 2016-03-10 | FMR LLC | Eleven Biotherapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2016-02-16 | Broadfin Capital, LLC | Eleven Biotherapeutics, Inc. | 54,450 | 0.0% | EDGAR |
SC 13G/A | 2016-02-12 | FMR LLC | Eleven Biotherapeutics, Inc. | 2,863,594 | 14.6% | EDGAR |
SC 13G/A | 2016-02-10 | FRANKLIN RESOURCES INC | Eleven Biotherapeutics, Inc. | 506,666 | 2.6% | EDGAR |
SC 13G/A | 2016-02-10 | FMR LLC | Eleven Biotherapeutics, Inc. | 1,218,856 | 6.2% | EDGAR |
SC 13G/A | 2016-02-09 | JAFCO Super V3 Investment Limited Partnership | Eleven Biotherapeutics, Inc. | 1,449,337 | 7.4% | EDGAR |
SC 13G/A | 2016-02-04 | FRANKLIN RESOURCES INC | Eleven Biotherapeutics, Inc. | 2,314,586 | 11.8% | EDGAR |
SC 13G | 2016-02-01 | SABBY MANAGEMENT, LLC | Eleven Biotherapeutics, Inc. | 1,061,999 | 5.4% | EDGAR |
SC 13G/A | 2016-01-12 | SABBY MANAGEMENT, LLC | Eleven Biotherapeutics, Inc. | 412,000 | 2.1% | EDGAR |
SC 13G | 2015-12-10 | FRANKLIN RESOURCES INC | Eleven Biotherapeutics, Inc. | 2,084,367 | 10.6% | EDGAR |
SC 13G/A | 2015-06-10 | FMR LLC | Eleven Biotherapeutics, Inc. | 2,877,394 | 14.9% | EDGAR |
SC 13G/A | 2015-02-17 | Broadfin Capital, LLC | Eleven Biotherapeutics, Inc. | 966,615 | 5.9% | EDGAR |
SC 13G/A | 2015-02-13 | FMR LLC | Eleven Biotherapeutics, Inc. | 1,765,112 | 9.8% | EDGAR |
SC 13G | 2015-02-13 | JAFCO Super V3 Investment Limited Partnership | Eleven Biotherapeutics, Inc. | 1,956,626 | 12.0% | EDGAR |
SC 13G/A | 2015-01-21 | SABBY MANAGEMENT, LLC | Eleven Biotherapeutics, Inc. | 653,877 | 3.6% | EDGAR |
SC 13G/A | 2015-01-21 | SABBY MANAGEMENT, LLC | Eleven Biotherapeutics, Inc. | 653,877 | 3.6% | EDGAR |
SC 13G | 2014-12-02 | SABBY MANAGEMENT, LLC | Eleven Biotherapeutics, Inc. | 653,877 | 3.6% | EDGAR |
SC 13G | 2014-05-12 | FMR LLC | Eleven Biotherapeutics, Inc. | 1,827,512 | 11.3% | EDGAR |